2024 Q2 Form 10-Q Financial Statement
#000178730624000079 Filed on May 14, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| Revenue | $30.86M | $49.57M | $2.781M |
| YoY Change | 494.57% | 1682.42% | |
| Cost Of Revenue | $3.464M | $3.256M | $783.0K |
| YoY Change | 346.39% | 315.84% | |
| Gross Profit | $27.39M | $46.31M | $1.998M |
| YoY Change | 520.62% | 2217.97% | |
| Gross Profit Margin | 88.77% | 93.43% | 71.84% |
| Selling, General & Admin | $58.17M | $54.79M | $42.92M |
| YoY Change | 26.58% | 27.67% | 95.03% |
| % of Gross Profit | 212.36% | 118.31% | 2148.05% |
| Research & Development | $19.30M | $23.14M | $35.35M |
| YoY Change | -23.48% | -34.53% | -12.99% |
| % of Gross Profit | 70.45% | 49.97% | 1769.02% |
| Depreciation & Amortization | $351.0K | $170.0K | $175.0K |
| YoY Change | 77.27% | -2.86% | 16.67% |
| % of Gross Profit | 1.28% | 0.37% | 8.76% |
| Operating Expenses | $77.47M | $77.94M | $79.05M |
| YoY Change | 7.67% | -1.41% | 26.22% |
| Operating Profit | -$50.08M | -$31.62M | -$76.27M |
| YoY Change | -24.99% | -58.54% | 21.77% |
| Interest Expense | -$7.484M | $7.480M | $7.042M |
| YoY Change | -201.84% | 6.22% | 283.13% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $5.229M | $4.044M | -$3.835M |
| YoY Change | -223.68% | -205.45% | 126.12% |
| Pretax Income | -$52.33M | -$35.06M | -$80.10M |
| YoY Change | -26.28% | -56.23% | 24.53% |
| Income Tax | $0.00 | $324.0K | $0.00 |
| % Of Pretax Income | |||
| Net Earnings | -$52.33M | -$35.38M | -$80.10M |
| YoY Change | -26.28% | -55.83% | 24.53% |
| Net Earnings / Revenue | -169.59% | -71.38% | -2880.26% |
| Basic Earnings Per Share | -$0.42 | -$0.32 | -$1.31 |
| Diluted Earnings Per Share | -$0.42 | -$0.32 | -$1.31 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 115.8M shares | 96.81M shares | 61.08M shares |
| Diluted Shares Outstanding | 123.5M shares | 111.0M shares | 61.17M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $362.4M | $403.9M | $332.4M |
| YoY Change | 34.9% | 21.5% | -3.26% |
| Cash & Equivalents | $84.27M | $190.1M | $81.41M |
| Short-Term Investments | $278.2M | $213.8M | $251.0M |
| Other Short-Term Assets | $14.86M | $13.80M | $13.95M |
| YoY Change | 18.75% | -1.12% | -6.71% |
| Inventory | $13.88M | $13.25M | $8.551M |
| Prepaid Expenses | |||
| Receivables | $43.41M | $37.15M | $12.77M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $434.6M | $468.1M | $367.7M |
| YoY Change | 40.7% | 27.3% | 2.44% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $1.347M | $1.369M | $2.070M |
| YoY Change | -27.85% | -33.86% | -3.81% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $6.063M | $6.250M | $7.000M |
| YoY Change | -11.0% | -10.71% | |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $595.0K | $596.0K | $78.00K |
| YoY Change | -0.17% | 664.1% | 0.0% |
| Total Long-Term Assets | $10.17M | $10.48M | $11.78M |
| YoY Change | -13.98% | -11.06% | 126.97% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $434.6M | $468.1M | $367.7M |
| Total Long-Term Assets | $10.17M | $10.48M | $11.78M |
| Total Assets | $444.8M | $478.5M | $379.5M |
| YoY Change | 38.69% | 26.11% | 4.22% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $7.943M | $12.97M | $12.49M |
| YoY Change | -53.7% | 3.88% | 0.15% |
| Accrued Expenses | $42.63M | $33.58M | $23.86M |
| YoY Change | 126.67% | 40.73% | 19.38% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $51.35M | $47.31M | $37.03M |
| YoY Change | 40.08% | 27.78% | 12.32% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $203.8M | $202.8M | $198.8M |
| YoY Change | 2.02% | 2.03% | 173.24% |
| Other Long-Term Liabilities | $194.0K | $306.0K | $3.938M |
| YoY Change | -94.83% | -92.23% | 20626.32% |
| Total Long-Term Liabilities | $204.0M | $203.1M | $198.8M |
| YoY Change | 2.12% | 2.19% | 173.17% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $51.35M | $47.31M | $37.03M |
| Total Long-Term Liabilities | $204.0M | $203.1M | $198.8M |
| Total Liabilities | $258.3M | $253.6M | $239.7M |
| YoY Change | 7.56% | 5.79% | 117.27% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$1.070B | -$1.017B | -$799.9M |
| YoY Change | 22.82% | 27.18% | 69.26% |
| Common Stock | $12.00K | $12.00K | $6.000K |
| YoY Change | 100.0% | 100.0% | 20.0% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $186.4M | $224.9M | $139.7M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $444.8M | $478.5M | $379.5M |
| YoY Change | 38.69% | 26.11% | 4.22% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$52.33M | -$35.38M | -$80.10M |
| YoY Change | -26.28% | -55.83% | 24.53% |
| Depreciation, Depletion And Amortization | $351.0K | $170.0K | $175.0K |
| YoY Change | 77.27% | -2.86% | 16.67% |
| Cash From Operating Activities | -$45.12M | -$31.60M | -$80.34M |
| YoY Change | -32.14% | -60.67% | 41.02% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $0.00 | $0.00 | $82.00K |
| YoY Change | -100.0% | -100.0% | -33.87% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | -$62.14M | -$28.70M | $107.8M |
| YoY Change | -169.51% | -126.61% | 599.26% |
| Cash From Investing Activities | -$62.14M | -$28.70M | $107.8M |
| YoY Change | -169.72% | -126.63% | 604.39% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 1.455M | $161.8M | $100.0K |
| YoY Change | 36.36% | 161664.0% | -99.32% |
| NET CHANGE | |||
| Cash From Operating Activities | -45.12M | -$31.60M | -$80.34M |
| Cash From Investing Activities | -62.14M | -$28.70M | $107.8M |
| Cash From Financing Activities | 1.455M | $161.8M | $100.0K |
| Net Change In Cash | -105.8M | $101.4M | $27.46M |
| YoY Change | -546.42% | 269.3% | -201.83% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$45.12M | -$31.60M | -$80.34M |
| Capital Expenditures | $0.00 | $0.00 | $82.00K |
| Free Cash Flow | -$45.12M | -$31.60M | -$80.43M |
| YoY Change | -32.42% | -60.71% | 40.85% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
28000000 | usd |
| CY2023Q1 | us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
0 | usd |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Revenues
Revenues
|
49569000 | usd |
| CY2023Q1 | us-gaap |
Revenues
Revenues
|
2781000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
3256000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
783000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
23141000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
35345000 | usd |
| CY2024Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
54794000 | usd |
| CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
42918000 | usd |
| CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
81191000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
79046000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-31622000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-76265000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
4044000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
3207000 | usd |
| CY2024Q1 | us-gaap |
Interest Expense
InterestExpense
|
7480000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
7042000 | usd |
| CY2024Q1 | us-gaap |
Income Loss Attributable To Parent
IncomeLossAttributableToParent
|
-35058000 | usd |
| CY2023Q1 | us-gaap |
Income Loss Attributable To Parent
IncomeLossAttributableToParent
|
-80100000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
324000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-35382000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-80100000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-116000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
724000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-21000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-52000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-137000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
672000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-35519000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-79428000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.32 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.32 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.31 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.31 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
111048525 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
111048525 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
61169089 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
61169089 | shares |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
88667000 | usd |
| CY2024Q1 | us-gaap |
Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
|
10820000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
161682000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
82000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
10030000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-116000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-21000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-35382000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
224942000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
209581000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
63000 | usd |
| CY2023Q1 | arqt |
Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
|
37000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
9479000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
724000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-52000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-80100000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
139732000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-35382000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-80100000 | usd |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
170000 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
175000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
97000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
87000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
188000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
188000 | usd |
| CY2024Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
1725000 | usd |
| CY2023Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
2161000 | usd |
| CY2024Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
1004000 | usd |
| CY2023Q1 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
994000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
10030000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9479000 | usd |
| CY2024Q1 | us-gaap |
Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
|
543000 | usd |
| CY2023Q1 | us-gaap |
Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
|
0 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
11347000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4311000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
113000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1037000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-5538000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2415000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
992000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
3376000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-332000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-4459000 | usd |
| CY2024Q1 | arqt |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-180000 | usd |
| CY2023Q1 | arqt |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-160000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-31603000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-80344000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
105952000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
39667000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
77255000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
|
147500000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
82000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-28697000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
107751000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
82000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
100000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
161682000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
0 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
161764000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
100000 | usd |
| CY2024Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-73000 | usd |
| CY2023Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-52000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
101391000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
27455000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
89323000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
54875000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
190714000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
82330000 | usd |
| CY2024Q1 | us-gaap |
Interest Paid Capitalized
InterestPaidCapitalized
|
6512000 | usd |
| CY2023Q1 | us-gaap |
Interest Paid Capitalized
InterestPaidCapitalized
|
5999000 | usd |
| CY2024Q1 | us-gaap |
Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
|
15789474 | shares |
| CY2024Q1 | us-gaap |
Sale Of Stock Price Per Share
SaleOfStockPricePerShare
|
9.50 | |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
161700000 | usd |
| CY2024Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1017300000 | usd |
| CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-981900000 | usd |
| CY2024Q1 | arqt |
Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
|
404500000 | usd |
| CY2023Q4 | arqt |
Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
|
272800000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to revenue recognition, accruals for research and development activities, stock-based compensation expense, and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.</span></div> | |
| CY2024Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
600000 | usd |
| CY2023Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
900000 | usd |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the condensed consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>balance sheets. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. | |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
21569000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2781000 | usd |
| CY2024Q1 | us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
28000000 | usd |
| CY2023Q1 | us-gaap |
Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
|
0 | usd |
| CY2024Q1 | us-gaap |
Revenues
Revenues
|
49569000 | usd |
| CY2023Q1 | us-gaap |
Revenues
Revenues
|
2781000 | usd |
| CY2024Q1 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
403866000 | usd |
| CY2023Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
271861000 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
190097000 | usd |
| CY2024Q1 | arqt |
Cash And Cash Equivalents Unrealized Gain
CashAndCashEquivalentsUnrealizedGain
|
0 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
190097000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
213785000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
25000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
41000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
213769000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
88395000 | usd |
| CY2023Q4 | arqt |
Cash And Cash Equivalents Unrealized Gain
CashAndCashEquivalentsUnrealizedGain
|
3000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
88398000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
183365000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
128000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
30000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
183463000 | usd |
| CY2023Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
|
P18M | |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
|
P18M | |
| CY2023Q1 | us-gaap |
Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
|
0 | usd |
| CY2023Q4 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Net
EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
|
849000 | usd |
| CY2024Q1 | us-gaap |
Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
|
543000 | usd |
| CY2024Q1 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Net
EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet
|
306000 | usd |
| CY2024Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
8202000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
9951000 | usd |
| CY2024Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
2303000 | usd |
| CY2023Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
486000 | usd |
| CY2024Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2742000 | usd |
| CY2023Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2697000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
13247000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
13134000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
1953000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
864000 | usd |
| CY2024Q1 | arqt |
Prepaid Clinical Trial Test Costs Current
PrepaidClinicalTrialTestCostsCurrent
|
1533000 | usd |
| CY2023Q4 | arqt |
Prepaid Clinical Trial Test Costs Current
PrepaidClinicalTrialTestCostsCurrent
|
1024000 | usd |
| CY2024Q1 | arqt |
Prepaid Copay Assistance Program
PrepaidCopayAssistanceProgram
|
0 | usd |
| CY2023Q4 | arqt |
Prepaid Copay Assistance Program
PrepaidCopayAssistanceProgram
|
8608000 | usd |
| CY2024Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
9692000 | usd |
| CY2023Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
8208000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
13178000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
18704000 | usd |
| CY2024Q1 | us-gaap |
Accrued Sales Commission Current
AccruedSalesCommissionCurrent
|
16651000 | usd |
| CY2023Q4 | us-gaap |
Accrued Sales Commission Current
AccruedSalesCommissionCurrent
|
11578000 | usd |
| CY2024Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
7476000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
14872000 | usd |
| CY2024Q1 | arqt |
Clinical Trial Accrual Current
ClinicalTrialAccrualCurrent
|
3425000 | usd |
| CY2023Q4 | arqt |
Clinical Trial Accrual Current
ClinicalTrialAccrualCurrent
|
4192000 | usd |
| CY2024Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
6032000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3299000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
33584000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
33941000 | usd |
| CY2024Q1 | us-gaap |
Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
|
500000 | usd |
| CY2024Q1 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
|
300000 | usd |
| CY2023Q4 | us-gaap |
Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
|
800000 | usd |
| CY2024Q1 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
200000000 | usd |
| CY2023Q4 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
200000000 | usd |
| CY2024Q1 | arqt |
Debt Instrument Accrued Final Fee
DebtInstrumentAccruedFinalFee
|
5625000 | usd |
| CY2023Q4 | arqt |
Debt Instrument Accrued Final Fee
DebtInstrumentAccruedFinalFee
|
4876000 | usd |
| CY2024Q1 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
2822000 | usd |
| CY2023Q4 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
3077000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
202803000 | usd |
| CY2023Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
201799000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
213900000 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
7919699 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
18.52 | |
| CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y4M6D | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
1435000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2904500 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.84 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
21863 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
3.82 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
5157144 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
23.15 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
171428 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
23.21 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
5473764 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.28 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y29D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
28716000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1936138 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
9.39 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y2M12D | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
8798000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
400000 | usd |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
500000 | usd |
| CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
6200000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.71 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
10.93 | |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10030000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9479000 | usd |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12646454 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
11260780 | shares |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false |
